Antiangiogenic therapy inhibits the vascular endothelial growth factor (VEGF), thereby inhibiting co-opting of tumor cells with pre-existing host vessels via VEGF upregulation in the CSF and thus inhibiting LMs [29, 30]. Here, VEGFA is linked to neoplasm.